Clovis Oncology Announces European Commission Authorization of Rubraca (rucaparib) for Women with Recurrent Ovarian Cancer Pharmaceutical Investing
Acorda Announces EMA Validation of the MAA Submission for INBRIJA™ (levodopa inhalation powder) Pharmaceutical Investing
Acerus Acquires Canadian Rights to Novel Pain Relief Product for Gynecological Procedures from Pharmanest Pharmaceutical Investing
GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD Pharmaceutical Investing
Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone Pharmaceutical Investing
Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse Pharmaceutical Investing
RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy Pharmaceutical Investing
“Avitas CBD Water, LLC” Rebranded As “Xanthic Beverages” and First Production to be Distributed to Over 500 Retail Locations Biotech Investing
IMFINZI (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer Pharmaceutical Investing
